SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
GWPRF - GW Pharmaceuticals PLC
An SI Board Since January 2006
Posts SubjectMarks Bans Symbol
1 2 0 GWPRF
Emcee:  jmhollen Type:  Moderated
Introduction Market Data Compact
GW Pharmaceuticals PLC (Gray GWPRF): is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of non-smoked prescription medicines derived from cannabis, including Sativex®, to meet patient needs in a wide range of therapeutic indications. The Group has also expanded its research to include the use of other controlled drugs in conjunction with its proprietary secure drug dispensing technology. GW’s lead product, Sativex®, was approved by Health Canada in April 2005 for the relief of neuropathic pain in Multiple Sclerosis (MS) and was launched in Canada in June 2005 by Bayer HealthCare who will exclusively market Sativex® in Canada.
Website: gwpharm.com
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1<b><i>US victory for cannabis-based cancer drug</b> Charlottejmhollen-1/4/2006
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News